Velaglucerase alfa

How it works

It replaces deficient beta-glucocerebrosidase activity, catalysing the breakdown of glucocerebroside that otherwise accumulates in macrophages.

Prescribing in practice

• Infusion-related and hypersensitivity reactions can occur, so infusions should be given with appropriate monitoring and the infusion rate adjusted or premedication used if reactions develop.
• It is administered as a regular intravenous infusion under specialist supervision, typically on an alternating-week schedule.
• Antibody formation can develop during treatment and may rarely affect response or tolerability.

Monitoring

Monitor haemoglobin, platelet count, organ volumes, and disease biomarkers periodically to assess treatment response.

Counselling the patient

• Report any reaction during or after the infusion, such as flushing, rash, or breathlessness.
• Attend regular infusion appointments to maintain disease control.
• This treatment manages Gaucher disease but does not cure it, so ongoing therapy is needed.

Evidence & guidelines

Velaglucerase alfa is licensed as enzyme replacement therapy for type 1 Gaucher disease, supported by clinical trial data.